Objective: Octreotide, a somatostatin analogue, has been shown to prevent angiogenesis in diverse in vitro models. We evaluated its effect on retinal neovascularization in vivo, using a neonatal rat retinopathy model. Methods: We used, on alternating days, hypoxia (10%O2) and hyperoxia (50%02) during the first 14 days of neonatal rats, to induce retinal neovascularization. Half of the rats were injected subcutaneously with octreotide 0.7 g/g BW twice daily. At day 18 the eyes were evaluated for the presence of epiretinal and vitreal hemorrhage, neovascularization and epiretinal proliferation. Octreotide pharmacokinetics and its effect on serum growth hormone (GH) and insulin-like growth factor I (IGF-I) were examined in 28 rats.
INTRODUCTION
Retinal neovascularization is a common feature of several eye diseases characterized by retinal hypoxia, such as proliferative diabetic retinopathy (PDR) and retinopathy of prematurity (ROP) . While the underlying pathology may be different in these conditions, the neovascular process itself leads to destruction of normal retina and eventually causes blindness. Growth hormone (GH) and insulin-like growth factor I (IGF-I) have been implicated in the pathogenesis of PDR (Lundbaek et al., 1970; Dills et al., 1991) . IGF-I has been shown to have angiogenic properties in animal models , and serum IGF-I levels have been reported to be elevated in patients with PDR (Merimee, Zapf and Froesch, 1983) . High vitreous levels of IGF-I and IGF binding proteins (IGFBPs) were found in patients with neovascular eye disease related to diabetes and to other ischemic retinal conditions (Meyer-Schwickerath et al., 1993) . In addition, a recent study demonstrated the essential role of GH and IGF-I in the development of retinal neovascularization in the ROP model in mice (Smith et al., 1997) .
Decades ago, before the advent of lasers, elimination of GH production by pituitary ablation was an accepted therapy for PDR (Bradley, Rees and Fager, 1965) . This approach was abandoned later because of obvious drawbacks, although several studies showed its effectiveness (Kohner et al., 1972) . Pharmacological inhibition of the GH secretion was shown to be an effective substitute for hypophysectomy in treatment of clinical PDR (McCombe et al., 1991) and experimental ROP (Smith et al., 1997) .
Octreotide, a long-acting somatostatin analogue, is a potent inhibitor of GH secretion with a plasma half-life of 90 minutes (Bauer et al., 1982) . Octreotide can be used to lower GH and IGF-I levels (Plewe et al., 1987) . In addition, octreotide has been shown to have direct antiangiogenic properties in human retinal endothelial cells culture (Grant, Caballero and Millard, 1993) and in the vascular growth model of the chick-embryo chorioallantoic membrane (Woltering et al., 1991) . Octreotide was tested in human clinical trials for treatment of both early (Kierkegaard et al., 1990) and severe PDR (Mallet et al., 1992; Lee et al., 1988 (Reynaud and Dorey, 1994; Penn, Tolman and Lowery, 1993) . Briefly, the animals were exposed on alternating days to hypoxia (10% O2-24h) and hyperoxia (50% O2-24h) (Pierce, Foley and Smith, 1996) interassay coefficients of variations were less than 5% and 10% respectively. Serum IGF-I was measured after extraction with acid-methanol (30tl serum and 7501 acid methanol) (Furlanetto and Marino, 1987 (7) 19% (10) 12% (6) 10% (5) (Fig. 1A) , on the border of the area which is typically affected by hypoxia in the ROP model, the PVR was found mainly in the posterior pole, associated with epiretinal hemorrhages. This finding supports our theory that the proliferative vitreoretinopathy (PVR) is induced by epiretinal hemorrhage (RH), thus should not necessarily originate from the periphery of the retina, while "pure" neovascularization (NV) seen on Figure 1B is probably induced by hypoxia-related growth factors produced by adjacent avascular retina, typically in the periphery. Bleeding may either cause epiretinal proliferation directly or may be a marker of severe retinal ischemia that is triggering epiretinal proliferation through a variety of growth factors. In any case, the sub-group of eyes with intraocular hemorrhages is specifically prone to epiretinal proliferation. We should stress that our definition of neovascularization was different from that used by some other groups. We defined neovascularization as a gross histological finding of blood vessels on the inner side of internal limiting membrane, while Smith et al. (1997) (Bauer et al., 1982) . We evaluated the effect of octreotide in 7-and 14-day animals, since it is at this age that the avascular retina is reacting to ischemia by up-regulation of IGF-I receptor and IGF binding proteins 2 and 3 (Averbukh et al., 1998) . It was impossible to take blood samples from the actual experimental animals without severely affecting them by stress and anemia. On the other hand, taking blood samples at the time of sacrifice (18 days) was probably irrelevant since the course of the neovascularization process is determined much earlier.
The primary effect of octreotide on neovascularization is mediated, at least to some extent, by GH secretion inhibition. GH levels were significantly reduced two hours after injection, but returned to normal nine hours after injection.
This very brief suppressive effect on GH levels is in accordance with previously published data (Wurzburger et al., 1992) . However, even two hours after injection, the achieved high level of octreotide failed to reduce serum IGF-I levels. It is of interest that treatment with octreotide at similar dose prevented kidney hypertrophy in diabetic rats (Flyvbjerg et al., 1989) while failing to change significantly serum levels of GH or IGF-I. Smith et al., showed recently that lowering of GH by another somatostatin analogue is effective in preventing hypoxia-induced neovascularization in the ROP model in mice. However, in spite of the demonstrated inhibition of GH secretion, at higher levels of somatostatin analogue there was a paradoxical relative increase in serum IGF-I levels that stayed unexplained (Smith et al., 1997) .
Octreotide was shown to have a direct inhibiting effect on IGF-I production in addition to its effect through the inhibition of GH secretion (Heyer et al., 1989) . It was previously reported that in cultured GH stimulated hepatocytes, IGF-I mRNA levels were significantly reduced in the presence of low octreotide concentrations (0.3 and 3gg/1) while high concentrations of octreotide (30 and 300gg/1) had no effect on IGF-I mRNA abundance (Serri et al., 1992) . In the present study, octreotide was injected at 12-hour intervals; therefore the lowest serum level of octreotide, just before the next injection, was approximately 6.6 gg/1 (extrapolated) which may be still too high for a direct suppressive effect on IGF-I production but too low for suppression of GH secretion. Moreover, withdrawal of octreotide, like somatostatin withdrawal, may generate a pulsatile GH release (Cella et al., 1996) which may explain the elevation of IGF-I levels at 9 and 14 hours after injection. Fluctuations in IGF-I levels, secondary to rebound elevation of GH after a brief suppression, may have a deleterious effect on retinal vasculature, promoting rather than suppressing neovascularization.
Finally, octreotide was found to have direct antiangiogenic properties in human retinal endothelial cell (HREC) culture (Grant et al., 1993b) and in a vascular growth model of the chickembryo chorioallantoic membrane (Woltering et al., 1991) . In cell culture of HREC stimulated by IGF-I and bFGF, [3H]thymidine incorporation was inhibited by octreotide (Grant et al., 1993b 
